Targeting ERBB2 mutations in solid tumors: biological and clinical implications

Preclinical data have shown that ERBB2 activating mutations are responsive to HER2 tyrosine kinase inhibitors. The aim of this study is to characterize the landscape of ERBB2 mutations in solid tumors and the potential efficacy of ERBB2 targeting. We analyzed the next-generation sequencing results f...

Descripción completa

Detalles Bibliográficos
Autores principales: Cousin, Sophie, Khalifa, Emmanuel, Crombe, Amandine, Laizet, Yech’an, Lucchesi, Carlo, Toulmonde, Maud, Le Moulec, Sylvestre, Auzanneau, Céline, Soubeyran, Isabelle, Italiano, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019715/
https://www.ncbi.nlm.nih.gov/pubmed/29941010
http://dx.doi.org/10.1186/s13045-018-0630-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019715/
https://www.ncbi.nlm.nih.gov/pubmed/29941010
http://dx.doi.org/10.1186/s13045-018-0630-4

Ejemplares similares